A Study LY2228820 for Recurrent Ovarian Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer
Sponsor: Eli Lilly and Company
This PHASE1/PHASE2 trial investigates Epithelial Ovarian Cancer and Fallopian Tube Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 13 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 8 earlier versions
-
Jun 2019 — Oct 2019 [monthly]
Completed PHASE1_PHASE2
-
Aug 2018 — Jun 2019 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .